We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Global Lateral Flow Assays Market to Reach USD 11.2 Billion by 2026 Due to Robust Demand for COVID-19 Screening Tests

By LabMedica International staff writers
Posted on 15 Jul 2021
The global market for lateral flow assays is projected to grow at a CAGR of 5.9% from an estimated USD 7.8 billion in 2020 to USD 11.2 billion by 2026, driven by high incidence of infectious conditions coupled with growing geriatric population, and increasing trend of point-of-care testing, especially COVID-19 screening tests.

These are the latest findings of a new market study published by Global Industry Analysts Inc. More...
(San Jose, CA, USA), a market research company.

Lateral flow assays are assays designed to effectively identify compounds of interest present in complex mixtures within 5-30 minutes. Lateral flow technology is fast emerging as a technique of choice for testing of infectious diseases given the numerous benefits the technology offers. The market is anticipated to also benefit from increasing popularity of self-diagnosis, a prominent trend that is propelling the demand for home-based lateral flow assay devices. Continuing technological advancements associated with lateral flow assays is also bolstering the market growth. These efforts are intended to improve these assays on the basis of selectivity, sensitivity and quantification. In addition, the integration of advanced quantification systems, new labels and simultaneous detection techniques is boosting growth. The market growth is further bolstered by the mayhem created by the COVID-19 pandemic, prompting governments to take aggressive steps for mass screening programs. The COVID-19 pandemic has presented an ideal growth opportunity for lateral flow assays due to robust demand for lateral flow assay-based screening tests.

Based on Product, the Kits & Reagents segment is projected to grow at a 6.1% CAGR to reach USD 9.6 billion by the end of the analysis period while the Lateral Flow Readers segment is projected to grow at a 4.9% CAGR for the next 7-year period. The Lateral Flow Readers segment currently accounts for a 17.9% share of the global Lateral Flow Assays market. In contrast to laboratory-based tests that are time-intensive, lateral flow test kits are portable, convenient to use, and require minimal training.

Geographically, the lateral flow assays market in the US is estimated to be valued at USD 3.3 billion in 2021 and currently accounts for a 38.64% share in the global market. The US market is at the forefront of adoption of lateral flow assays, supported by the rising prevalence of infectious conditions like tuberculosis and Lyme disease, along with increasing mortality rate linked with AIDS. China’s lateral flow assays market is estimated to reach a market size of USD 872.4 million in 2026, growing at a CAGR of 8.8% through the analysis period. Among the other noteworthy markets for lateral flow assays are Japan and Canada, which are each forecasted to grow at 3.8% and 5.5%, respectively over the analysis period. Within Europe, Germany’s lateral flow assays market is forecasted to grow at approximately 4.8% CAGR, while the Rest of Europe market will reach USD 917 million by the end of the analysis period. A host of factors are contributing to rapid uptake of lateral flow assays in developing regions, especially Asia-Pacific. While the demand for these products is primarily being driven by growing healthcare expenditure and increased demand for diagnostics, other factors including rising healthcare awareness and subsequent increase in demand for healthcare services are also contributing to the increase in demand.

Related Links:
Global Industry Analysts Inc.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Portable Electronic Pipette
Mini 96
Gold Member
Hematology Analyzer
Medonic M32B
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.